Novo Nordisk Stock Crashes 22% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. Business December 20, 2024 Updated: 8 hours ago By Market Watch Share FacebookTwitterPinterestWhatsApp Novo Nordisk stock fell sharply after the Ozempic maker’s experimental obesity drug CagriSema disappointed investors. Eli Lilly Shares Soar. Read more… Share FacebookTwitterPinterestWhatsApp Latest news US It’s Not What We’d Agreed To Breitbart - December 20, 2024 Sports Biden Considering Commuting Sentences of Men on Death Row Breitbart - December 20, 2024 World AP Slammed for Saying Car Drove into Crowd at Christmas Market Breitbart - December 20, 2024 US Federal Agents Raid N.Y.C. ‘Hideout’ Of Tren de Aragua Gang Members After GPS Ankle Monitor Leads Them There – One America News Network One America - December 20, 2024 Related news Technology Design Within Reach Promo Codes: Extra 20% Off Wired - December 21, 2024 US It’s Not What We’d Agreed To Breitbart - December 20, 2024 Sports Biden Considering Commuting Sentences of Men on Death Row Breitbart - December 20, 2024 World AP Slammed for Saying Car Drove into Crowd at Christmas Market Breitbart - December 20, 2024 LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment.
